APLT241220P7500
- 5.80
- +0.37+6.81%
Applied Therapeutics Newsroom
Optimistic Outlook for Applied Therapeutics Despite FDA Setback
Applied Therapeutics Faces FDA Challenges With Govorestat
Express News | Applied Therapeutics: Following Issuance of a Complete Response Letter by FDA, Received Warning Letter Limited to at-007-1002 Study
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Netflix To Rally More Than 7%? Here Are 10 Top Analyst Forecasts For Monday
Express News | Applied Therapeutics Inc : UBS Cuts Target Price to $2 From $13
Express News | Applied Therapeutics Inc : UBS Cuts to Neutral From Buy
Applied Therapeutics Price Target Lowered to $5 From $14 at Baird
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
Applied Therapeutics Downgraded to Sector Perform From Outperform at RBC
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow
Applied Therapeutics Price Target Cut to $8.00/Share From $13.00 by Citigroup
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup
Express News | Citigroup Maintains Buy on Applied Therapeutics, Lowers Price Target to $8
Applied Therapeutics Options Spot-On: On November 29th, 52,978 Contracts Were Traded, With 105.7K Open Interest
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%
Dow, S&P 500 End November at Record Highs
Applied Therapeutics Is Maintained at Outperform by Baird
Baird Maintains Outperform on Applied Therapeutics, Lowers Price Target to $5